Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Market Scope regularly updates its list of ophthalmic meetings to keep the information current. Please contact us at matthewdouty@market-scope.com if we do not have your meeting listed. Thank you.
Heidelberg Engineering announced Oct. 14 that the US FDA had granted 510(k) clearance to its Flex Module for the Spectralis diagnostic imaging platform. The Flex Module mounts the Spectralis to a m...
Tarsus Pharmaceuticals, maker of Xdemvy for Demodex blepharitis, announced Nov. 5 that it had appointed Elizabeth Yeu, MD, as chief medical officer. Yeu had served as Tarsus’ chief medical advisor ...
German company Carl Zeiss Meditec opened a new state-of-the-art research and production facility on Oct. 1 in Chesterfield, Missouri, expanding its footprint in the city, which is part of the St. L...
Harrow reported Sept. 25 that it is creating nearly 150 new jobs as it expands its corporate headquarters in Nashville, Tennessee. The move follows the company increasing its total leased space in ...
Oculus has announced the addition of frequency doubling perimetry (FDP) to its Easyfield VR visual field diagnostic headset. The German ophthalmic diagnostic company, with US headquarters in Arling...
Iridex reported Oct. 3 that it had appointed Patrick Mercer as chief executive officer, to go along with his role as president, effective Oct. 1. Mercer had also served as the company’s chief opera...
Australian drug developer Opthea announced Oct. 8 that it had appointed Parisa Zamiri, MD, PhD, as chief medical officer. Zamiri, an ophthalmologist, has clinical experience in medical retina, immu...
Oak Hill Bio, of Cambridge, Massachusetts, announced Oct. 7 that it had promoted Josh Distler, JD, to chief executive officer. Distler is a co-founder of Oak Hill and previously served as the compa...
German company Carl Zeiss Meditec opened a new state-of-the-art research and production facility on Oct. 1 in Chesterfield, Missouri, expanding its footprint in the city, which is part of the St. L...
Switzerland’s Rejuveron Life Sciences announced Sept. 19 that it had rebranded as Centenara Labs. The company develops and invests in therapeutic candidates to promote healthy aging. Centenara said...
Eyconis announced Sept. 19 that it had appointed Mark J. Bachleda, PharmD, MBA, as chief executive officer and a member of its board of directors. Bachleda has served in executive leadership roles ...
Luxa Biotechnology announced Oct. 1 that it had appointed Keith Dionne, PhD, as chief executive officer. Luxa, of Fort Lee, New Jersey, is advancing RPESC-RPE-4W, a cell product derived from adult ...
Italy’s AAVantgarde Bio announced Sept. 9 that it had appointed Jayashree Sahni, MD, FRCOphth, EMBA, as chief medical officer. Sahni, a retina specialist, was senior global program clinical head at...
Harrow reported Sept. 25 that it is creating nearly 150 new jobs as it expands its corporate headquarters in Nashville, Tennessee. The move follows the company increasing its total leased space in ...
Bausch + Lomb is working with Goldman Sachs to explore a sale of the company, the Financial Times reported Sept. 14, with private equity the most likely buyer. The move is being evaluated as a way ...
Belgium’s iStar Medical announced Sept. 4 that it had appointed Richard Beckman, MD, as chief medical officer and member of the company’s board. Beckman most recently served as CMO of Adverum Biote...
Belite Bio announced Sept. 1 that it had appointed Hendrik P.N. Scholl, MD, MA, as chief medical officer, effective immediately. Scholl specializes in inherited retinal and macular dystrophies, and...
BioCryst Pharmaceuticals, of Durham, North Carolina, announced Sept. 5 that it had appointed Donald S. Fong, MD, MPH, as the company’s new chief medical officer, effective immediately. Fong joined ...
Acelyrin reported Aug. 13 that it would reduce its workforce and shift its pipeline strategy to prioritize lonigutamab, its candidate for thyroid eye disease (TED). The announcement came amid posit...
SalioGen Therapeutics announced Aug. 19 that it had appointed Kalliopi “Kali” Stasi, MD, PhD, as chief medical officer. SalioGen said Stasi will be responsible for bringing the company’s SGT-1001, ...
Ireland-based Mallinckrodt announced Aug. 6 that its H.P. Acthar Gel single-dose prefilled SelfJect injector was available in the US. The US FDA approved the supplemental new drug application for t...
Eyenovia, of New York, announced July 23 that it had entered into a collaboration agreement with Japan’s Senju Pharmaceutical to develop Senju’s corneal epithelial wound healing candidate, SJP-0035...
The 2024 Octane Ophthalmology Tech Forum changed up its program from previous years, putting more focus on practice management and moving to a new location: the VEA Newport Beach, in Newport Beach,...
Germany’s TME Pharma, a clinical-stage cancer company, announced July 22 that it planned to spin off its asset NOX-E36 to advance it for eye disease. NOX-E36 is an L-stereoisomer RNA aptamer inhibi...
Beacon Therapeutics announced July 24 that it had named Lance Baldo, MD, as chief executive officer, effective Aug. 12, 2024. Most recently, Baldo served as chief medical officer at Freenome, an ea...
Market Scope announced July 11 that Kristen Harmon Ingenito, MBA, had been appointed chief executive officer. Dave Harmon, founder of Market Scope, will serve as chief financial officer and data se...
Bausch + Lomb announced July 23 that it had acquired dry eye diagnostic company Trukera Medical from its private equity owner, AccelMed Partners, and other shareholders. No financial details were d...
Digital health care company Eyenuk, of Los Angeles, California, announced July 18 that it had appointed Bryan Haardt as chief executive officer. Paul Praino, who had been serving as Eyenuk’s interi...
Sydnexis, of Del Mar, California, announced July 16 that Perry J. Sternberg had been appointed chief executive officer and as a member of the board of directors. He will join the company on Aug. 5,...
Alkeus Pharmaceuticals announced July 2 that Michel Dahan had joined the company as president and chief executive officer. He had served as a member of the board since January 2023. Alkeus, of Camb...
Japan’s Nidek announced June 3 that it had launched the RS-1 Glauvas OCT system. The device is CE marked as a Class IIa device. Nidek said the RS-1 Glauvas’ streamlined workflow and advanced analyt...
Skye Bioscience reported June 10 that it was discontinuing its ophthalmology program after its synthetic cannabinoid derivative SBI-100, a glaucoma drop candidate, failed to meet its Phase IIa prim...
Regenxbio announced June 12 that its chief operating officer, Curran Simpson, had been appointed president and chief executive officer. He will also join the board of directors. Co-founder Kenneth ...
Many companies participate in ARVO’s annual meeting to catch the attention of external researchers and propel their research program or clinical trials forward. Two such companies in 2024 were John...
OcuTerra Therapeutics, of Boston, Massachusetts, announced May 1 on LinkedIn that it would wind down operations. The company had been developing nesvategrast (OTT166 5%), an eye drop candidate for ...
Topcon Healthcare announced April 26 that it had appointed Ali Tafreshi as CEO and president. The company said Tafreshi will lead the company’s focus on “oculomics”—diagnosing not just eye health b...
Eyenovia reported April 8 that it is exploring strategic alternatives to maximize shareholder value, even as it rolls out Mydcombi for pupil dilation and prepares to launch its clobetasol propionat...
Alexion, the rare disease unit of AstraZeneca, announced March 25 that the US FDA had approved its long-acting C5 complement inhibitor Ultomiris (ravulizumab-cwvz) for adults with neuromyelitis opt...
Ocular Therapeutix announced April 15 that its executive chairman, Pravin Dugel, MD, would assume the roles of president and chief executive officer, and that Antony Mattessich is stepping down, ef...
US-based private equity firm Warburg Pincus and Appasamy Associates announced April 10 that Warburg had bought a controlling stake in the Indian ophthalmic company. Financial details were not discl...
Eyenovia reported April 8 that it is exploring strategic alternatives to maximize shareholder value, even as it rolls out Mydcombi for pupil dilation and prepares to launch its clobetasol propionat...
Israel’s Beyeonics Vision announced March 28 that it had appointed A. Burton Tripathi, PhD, as its new chief executive officer. Tripathi was formerly CEO of TrueVision 3D Surgical. After Alcon acqu...
France’s Nicox announced that it had appointed Gavin Spencer, PhD, as chief executive officer, effective Feb. 28. Spencer was most recently executive vice president, chief business officer, and hea...
Alcon announced March 26 that Terry Kim, MD, would join the company in April as chief medical officer (CMO) and head of global medical safety. Kim, who specializes in cornea, cataract, and refracti...
Amring Pharmaceuticals announced March 4 that it had changed its name to Nordic Pharma Inc., following the change in ownership of the company from Sever Life Sciences to Nordic Group in June 2023. ...
Clearside Biomedical announced March 18 that it had appointed Victor Chong, MD, MBA, as chief medical officer. Chong, a retina specialist, most recently served as vice president, global head of ret...
Germany’s VSY Biotechnology launched its Enova Maestro trifocal toric preloaded intraocular lens (IOL) at the European Society of Cataract and Refractive Surgeons (ESCRS) Winter Meeting, held Feb. ...
RVL Pharmaceuticals Inc., of New Jersey, formerly a subsidiary of publicly held RVL Pharmaceuticals plc, is now owned by Athyrium Capital Management after emerging from Chapter 11 bankruptcy procee...
Surface Ophthalmics, of Pleasanton, California, has named co-founder and director Richard Lindstrom, MD, as chairman. The company, which is developing dry eye drugs, was formed in 2018. Lindstrom w...
Vital Tears announced March 6 that it had appointed Joseph Tauber, MD, as its chief medical officer. In 2023, Vital Tears added mobile phlebotomy services to its system of providing autologous seru...
EyePoint Pharmaceuticals announced March 4 that it had appointed retina specialist Ramiro Ribeiro, MD, PhD, as chief medical officer. Ribeiro succeeds Dario Paggiarino, MD, who had served in the ro...
AbbVie reported Feb. 20 that it had named Robert A. Michael—the company’s current president and chief operating officer—to succeed Richard A. Gonzalez as chief executive officer. Michael also will ...
Ocular Therapeutix announced Feb. 22 that it had entered into a securities purchase agreement with institutional investors for a private placement of shares, with gross proceeds of approximately $3...
Chinese biotech company LianBio announced Feb. 13 that it would wind down operations—including selling its pipeline assets, delisting its American Depositary Shares from the Nasdaq, and cutting its...
Eyenovia, of New York, announced Feb. 13 that the company’s facility in Redwood City, California, had successfully completed US FDA inspection for approval as a commercial manufacturing facility. T...
Amneal Pharmaceuticals announced Jan. 10 that it had received US FDA approval for and launched generic fluorometholone eye drops. The product is indicated for the treatment of corticosteroid-respon...
Chinese biotech company LianBio announced Feb. 13 that it would wind down operations—including selling its pipeline assets, delisting its American Depositary Shares from the Nasdaq, and cutting its...
Eyenovia, of New York, announced Feb. 13 that the company’s facility in Redwood City, California, had successfully completed US FDA inspection for approval as a commercial manufacturing facility. T...
Ace Vision Group announced Feb. 13 that it had named Val Kolesnitchenko, MD, as chief scientific officer. Most recently, Kolesnitchenko held the position of executive director of global scientific ...
EyeCare Partners, of St. Louis, Missouri, announced Jan. 25 that Chris Throckmorton had been named chief executive officer, succeeding Ben Breier, who was serving as interim CEO. The change took ef...
Stuart Therapeutics, of Stuart, Florida, reported Feb. 1 that it had appointed Jodi Luchs, MD, as chief medical officer. Luchs is a board-certified, fellowship-trained ophthalmologist with a subspe...
German company Carl Zeiss Meditec, part of the Zeiss Group, reported Feb. 1 that it had settled a lawsuit it brought against Topcon Medical Systems and Topcon Healthcare Solutions, US subsidiaries ...
Australian drug developer Opthea announced Feb. 1 the appointment of Julie Clark, MD, as senior vice president of clinical development. Clark has spent 15 years developing retinal drugs, being invo...
Market Scope asked surgeons and industry participants to select the top story for 2023. Below are their choices. Bausch + Lomb Makes Big Moves, Adding Product Lines and Building Partnerships MAC Tu...
Silicon Valley Bank, of Santa Clara, California, was seized by the US government on March 11, 2023, in the second largest bank failure in US history. The failure caused a great deal of initial pani...
Japanese drugmaker Astellas made the single largest transaction in the 2023 ophthalmic market when it acquired Iveric Bio for $5.9 billion. The deal was announced April 30 and closed on July 11, wh...
Santen Pharmaceutical, Astellas Pharma, and Nitto Medic were among Japanese ophthalmic drugmakers facing delays in manufacturing drugs in the aftermath of a massive earthquake on New Year’s Day, ne...
Belgium’s Oxurion announced Dec. 28 that it had avoided bankruptcy through an agreement with its main creditor, Atlas Special Opportunities. Atlas will continue to fund Oxurion under an existing 20...
Maker of Sophi Phaco Machines UK-based Rayner announced Jan. 17 that it had acquired Switzerland’s This AG, the maker of Sophi phacoemulsification machines. No financial details were disclosed. Sop...
Belgium’s Oxurion announced Dec. 28 that it had avoided bankruptcy through an agreement with its main creditor, Atlas Special Opportunities. Atlas will continue to fund Oxurion under an existing 20...
Centricity Vision, of Carlsbad, California, announced Dec. 20 that Leonard Borrmann, PharmD, formerly the company’s head of research and development, had been named chief executive officer. Borrman...
Spain’s SpliceBio announced Jan. 3 that it had appointed Aniz Girach, MD, as chief medical officer. SpliceBio’s protein splicing platform offers the potential to address diseases where the genetic ...
KeraLink International, a nonprofit group focused on eradicating global corneal blindness, announced Dec. 11 that it had launched a Cornea Technology Accelerator, open to entrepreneurs and innovato...
Genentech, a member of the Roche Group, reported Dec. 12 that it had appointed Ashley Magargee as chief executive officer. Magargee has been serving as interim CEO since Alexander Hardy stepped dow...
InMed Pharmaceuticals, of Vancouver, Canada, announced Nov. 29 that it had added to its pipeline INM-089, a cannabinoid analog, to investigate its potential treatment effect in age-related macular ...
Corza Medical reported Nov. 30 that it had opened a new Ophthalmology Center of Technology and Innovation in Fenton, Missouri, which is part of the St. Louis region. The facility, which covers 30 t...
Belgium’s Oxurion reported Nov. 20 that it would take the steps necessary to file for bankruptcy after its plasma kallikrein inhibitor THR-149 failed to reach its primary endpoint of improvement in...
Corza Medical reported Nov. 30 that it had opened a new Ophthalmology Center of Technology and Innovation in Fenton, Missouri, which is part of the St. Louis region. The facility, which covers 30 t...
Enzene Biosciences, based in Pune, India, announced in November that it had launched a ranibizumab biosimilar for the treatment of wet age-related macular degeneration (AMD). The product references...
SpyGlass Pharma announced Dec. 5 that it had appointed Margot Goodkin, MD, PhD, as chief medical officer. Goodkin is a glaucoma fellowship-trained ophthalmologist and biopharmaceutical industry vet...
Generation Bio, of Cambridge, Massachusetts, reported Nov. 29 that it would stop advancing its pipeline of retinal candidates as it redefines its strategic priorities and reduces its workforce by 4...
Belgium’s Oxurion reported Nov. 20 that it would take the steps necessary to file for bankruptcy after its plasma kallikrein inhibitor THR-149 failed to reach its primary endpoint of improvement in...
The University of California, San Francisco (UCSF), held its Ophthalmology Showcase on Nov. 3 to highlight both the school’s history of ophthalmic innovation and its role in future advancements. Th...
Specialty pharma company Padagis announced Oct. 13 the launch of its brinzolamide ophthalmic suspension, a generic version of Novartis’ Azopt for glaucoma. Padagis, with offices in the US and Israe...
Regenxbio announced in its Q3-2023 financial statement on Nov. 8 that it would cut its workforce by approximately 15 percent while prioritizing three gene therapy candidates with the largest commer...
Ascidian Therapeutics announced Nov. 8 that it had raised $40 million in Series A extension funding from life sciences venture capital company Apple Tree Partners. Ascidian, of Boston, Massachusett...
Laser company Ace Vision Group announced Nov. 1 that it had named Rob Kissling, MD, as chief medical officer. Most recently, Kissling served as vice president of clinical and medical affairs at Bau...
EyeCheq announced Nov. 2 that it had appointed Ruwan Silva, MD, as chief medical officer. Silva completed his residency in ophthalmology at Bascom Palmer Eye Institute in Miami, Florida, and his vi...
Ocuphire Pharma announced Nov. 1 that it had appointed George Magrath, MD, as chief executive officer and a member of its board of directors. Magrath succeeds Rick Rodgers, interim CEO and presiden...
Australian company Opthea announced Oct. 27 that the company’s chief executive officer, Megan Baldwin, PhD, will transition to founder and chief innovation officer, and that US-based Frederic Guera...
Théa Pharma, the US subsidiary of France’s Laboratoires Théa, announced the launch Sept. 26 of once-daily Iyuzeh (latanoprost ophthalmic solution) 0.005% in the US market. Iyuzeh is the first prese...
Swiss company Novartis spun out Sandoz, its generics and biosimilars business, on Oct. 4. Sandoz is a leading provider in the US of generic ophthalmic drugs for a wide range of eye diseases. It has...
Sight Sciences, of Menlo Park, California, has informed its employees that it will cut its workforce of 250 by 25 employees as it awaits a final decision by five of the seven Medicare Administrativ...
STAAR Surgical reported Oct. 17 that October 2023 marked the 30th anniversary of the first implantations of the company’s Implantable Collamer Lens (ICL). The lens is intended to be implanted betwe...
Total Vision, an affiliation of 59 independent optometry practices in California, has sued VSP Vision, accusing the insurer of abusing its market power to stifle competition and pressure practices ...
France’s Pixium Vision reported Oct. 9 that the Commercial Court of Paris had opened safeguard proceedings—similar to bankruptcy protection—for the company, after Pixium said it might not be able t...
HumanOptics, of Erlangen, Germany, announced Oct. 4 that it had named Alexander Berka as its chief executive officer. HumanOptics markets an artificial iris and the Triva, Torica, and Aspria intrao...
Switzerland’s Haag-Streit Group announced Oct. 3 that it had appointed Olaf Felske as the new chief executive officer of Haag-Streit USA, its division based in Mason, Ohio. Haag-Streit USA distribu...
HelpMeSee, a global nonprofit group that provides simulation training in low-cost cataract surgery, announced Oct. 10 that it had named Bonnie An Henderson, MD, as president and chief executive off...
Israel’s Beyeonics announced Oct. 4 that ophthalmic industry veteran Joseph C. Papa had joined the company as chairman of the board of Beyeonics Surgical and board member of Beyeonics Vision. Papa ...
Aura Biosciences, of Boston, Massachusetts, announced Oct. 2 that it had appointed J. Jill Hopkins, MD, as chief medical officer and president of research and development. The company also announce...
Mati Therapeutics, of Austin, Texas, reported Sept. 12 that it had completed a 10 thousand square foot facility in Bryan, Texas, to manufacture the company’s Evolute sustained drug delivery platfor...
Nanoscope Therapeutics, of Dallas, announced Sept. 21 that it had appointed Samuel Barone, MD, as chief medical officer. Barone was most recently chief medical officer at Gemini Therapeutics, prior...
Carl Zeiss Meditec announced Aug. 23 that more than 8 million eyes had been treated with the company’s SMILE procedure through the first half of 2023. SMILE, short for small-incision lenticule extr...
UK ophthalmic company Oxular Limited announced Sept. 11 that it had appointed Mark Gaffney as chief executive officer and a member of the board of directors. Gaffney succeeds Thomas Cavanagh, who O...
Neurotech Pharmaceuticals reported Sept. 13 that Alex Gorsky had been elected to its board as lead director. Gorsky, former chairman and chief executive officer of Johnson & Johnson, stepped down f...
Apellis Pharmaceuticals, maker of the intravitreal drug Syfovre (pegcetacoplan) for geographic atrophy (GA), announced Aug. 29 that it would lay off about 225 employees—a quarter of its workforce—a...
Iridex announced Aug. 29 that it would undergo a review of strategic alternatives, with Piper Sandler acting as financial advisor for the process. The Mountain View, California, ophthalmic laser co...
Nancy Lurker, executive vice chair of EyePoint Pharmaceuticals, sat with Market Scope at the 2023 meeting of the American Society of Retina Specialists (ASRS) and reflected on the challenges of run...
Firas Rahhal, MD, moderator and co-chair of the 2023 OIS Retina meeting, said he didn’t want company pitches to focus only on their science—and most of them didn’t. “The point of pitches at OIS (fo...
Boston-headquartered Intergalactic Therapeutics has laid off all its employees and is exploring options, the Boston Business Journal reported Aug. 1. Intergalactic was developing a non-viral gene t...
New York’s Icahn School of Medicine at Mount Sinai announced July 5 that it had launched the Center for Ophthalmic Artificial Intelligence and Human Health. The center will incorporate AI into educ...
HelpMeSee, a global nonprofit group that provides simulation training in low-cost cataract surgery, announced Aug. 15 that it had named Bonnie Henderson, MD, as interim president and chief executiv...
Boston-headquartered Intergalactic Therapeutics has laid off all its employees and is exploring options, the Boston Business Journal reported Aug. 1. Intergalactic was developing a non-viral gene t...
Complement Therapeutics (CTx) announced Aug. 3 that it had appointed Parisa Zamiri, MD, PhD, as chief medical officer. Zamiri is an ophthalmologist by training, with clinical experience in medical ...
BVI Medical announced July 18 the opening of its new, state of the art intraocular lens manufacturing facility in Liège, Belgium. The company, headquartered in Waltham, Massachusetts, said the new ...
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.